These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36696749)

  • 1. Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT).
    Gargiulo P; Basile C; Cesaro A; Marzano F; Buonocore D; Asile G; Abbate V; Vicidomini F; Paolillo S; Spaccarotella CAM; Catalano A; Spirito G; Merlini PA; Maloberti A; Iannuzzo G; Ciccone MM; Zito AP; Paloscia L; D'Alleva A; Varbella F; Corleto A; Brunetti ND; Corbo MD; Calabrò P; Indolfi C; Perrone-Filardi P
    Atherosclerosis; 2023 Feb; 366():32-39. PubMed ID: 36696749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels.
    Svensson MK; James S; Ravn-Fischer A; Villa G; Schalin L; Cars T; Gustafsson S; Hagström E
    Ups J Med Sci; 2024; 129():. PubMed ID: 38327639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence with long-term PCSK9 inhibitor treatment and its effectiveness in familial hypercholesterolaemia: data from the SAFEHEART study.
    Alonso R; Arroyo-Olivares R; Muñiz-Grijalvo O; Díaz-Díaz JL; Muñoz-Torrero JS; Romero MJ; de Andrés R; Zambón D; Mañas MD; Fuentes-Jiménez F; Aguado R; Alvarez-Baños P; Arrieta F; Gonzalez-Bustos P; Cepeda J; Martin-Ordiales M; Mosquera D; Michan A; de Isla LP; Argueso R; Mata P
    Eur J Prev Cardiol; 2023 Mar; 30(4):320-328. PubMed ID: 36416136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
    Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
    Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E; Daum A; Yosefy C
    Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors.
    Hines DM; Rane P; Patel J; Harrison DJ; Wade RL
    Vasc Health Risk Manag; 2018; 14():409-418. PubMed ID: 30573963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
    Rallidis LS; Skoumas I; Liberopoulos EN; Vlachopoulos C; Kiouri E; Koutagiar I; Anastasiou G; Kosmas N; Elisaf MS; Tousoulis D; Iliodromitis E
    Hellenic J Cardiol; 2020; 61(4):241-245. PubMed ID: 31783124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice.
    Gayoso-Rey M; Díaz-Trastoy O; Romero-Ventosa EY; García-Beloso N; González-Freire L; Lorenzo-Lorenzo K; Mantiñán-Gil B; Palmeiro-Carballeira R; Bravo-Amaro M; López-Gil-Otero MDM; Martínez-Reglero C; Crespo-Diz C; Fernández-Catalina P; Piñeiro Corrales G
    Clin Ther; 2021 Apr; 43(4):e111-e121. PubMed ID: 33712271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
    Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C
    Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Secondary Prevention Patients Eligible for PCSK9 Inhibitors Therapy According to the Routine Clinical Practice in Spain.
    Cosin-Sales J; Sidelnikov E; Villamayor S; Fernández M; Merino-Montero S; Zamora A
    Adv Ther; 2023 Jun; 40(6):2710-2724. PubMed ID: 36525203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
    Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
    Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study.
    Piccinni C; Antonazzo IC; Maggioni AP; Pedrini A; Calabria S; Ronconi G; Dondi L; Martini N; Roberto G; Sampietro T; Sbrana F; Pino BD; Bigazzi F; Surdo GL; Volpi E; Biagini S; Gini R
    Clin Drug Investig; 2020 Feb; 40(2):173-181. PubMed ID: 31797311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
    Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
    [No Abstract]   [Full Text] [Related]  

  • 19. PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease.
    Delialis D; Dimopoulou MA; Papaioannou M; Kotsira G; Maneta E; Mavraganis G; Loutos C; Georgiopoulos G; Stamatelopoulos K
    Curr Pharm Des; 2023; 29(23):1802-1824. PubMed ID: 37055909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
    Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
    J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.